Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload
Norimichi Koitabashi, Thomas Danner, Ari L. Zaiman, Yigal M. Pinto, Janelle Rowell, Joseph Mankowski, Dou Zhang, Taishi Nakamura, Eiki Takimoto, David A. Kass
Norimichi Koitabashi, Thomas Danner, Ari L. Zaiman, Yigal M. Pinto, Janelle Rowell, Joseph Mankowski, Dou Zhang, Taishi Nakamura, Eiki Takimoto, David A. Kass
View: Text | PDF
Research Article Cardiology

Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload

  • Text
  • PDF
Abstract

The cardiac pathological response to sustained pressure overload involves myocyte hypertrophy and dysfunction along with interstitial changes such as fibrosis and reduced capillary density. These changes are orchestrated by mechanical forces and factors secreted between cells. One such secreted factor is TGF-β, which is generated by and interacts with multiple cell types. Here we have shown that TGF-β suppression in cardiomyocytes was required to protect against maladaptive remodeling and involved noncanonical (non–Smad-related) signaling. Mouse hearts subjected to pressure overload and treated with a TGF-β–neutralizing Ab had suppressed Smad activation in the interstitium but not in myocytes, and noncanonical (TGF-β–activated kinase 1 [TAK1]) activation remained. Although fibrosis was greatly reduced, chamber dysfunction and dilation persisted. Induced myocyte knockdown of TGF-β type 2 receptor (TβR2) blocked all maladaptive responses, inhibiting myocyte and interstitial Smad and TAK1. Myocyte knockdown of TβR1 suppressed myocyte but not interstitial Smad, nor TAK1, modestly reducing fibrosis without improving chamber function or hypertrophy. Only TβR2 knockdown preserved capillary density after pressure overload, enhancing BMP7, a regulator of the endothelial-mesenchymal transition. BMP7 enhancement also was coupled to TAK1 suppression. Thus, myocyte targeting is required to modulate TGF-β in hearts subjected to pressure overload, with noncanonical pathways predominantly affecting the maladaptive hypertrophy/dysfunction.

Authors

Norimichi Koitabashi, Thomas Danner, Ari L. Zaiman, Yigal M. Pinto, Janelle Rowell, Joseph Mankowski, Dou Zhang, Taishi Nakamura, Eiki Takimoto, David A. Kass

×

Figure 3

N-Ab suppresses Smad activation in noncardiomyocytes.

Options: View larger image (or click on image) Download as PowerPoint
N-Ab suppresses Smad activation in noncardiomyocytes.
(A) Western blot f...
(A) Western blot for Smad3 and TAK1 phosphorylation in 9-week TAC myocardium with N-Ab or C-Ab. Summary data shows reduced activation of Smad3, but not TAK1. n = 6 per group. *P < 0.01 vs. sham; †P < 0.05 vs. TAC plus C-Ab. (B–E) Phospho-Smad3 immunostaining (green) in 9-week TAC myocardium treated with C-Ab (B and D) and N-Ab (C and E). Scale bars: 50 μm. (B and C) Smad3 activation in vascular SMCs was suppressed by N-Ab treatment. Red, SMA (SMCs); blue, DAPI; white, WGA. White arrows, SMC Smad3 activation; yellow arrows, cardiomyocyte Smad activation. (D and E) Smad3 activation in cardiac fibroblasts was suppressed by N-Ab. Red, vimentin (cardiac fibroblasts); blue, DAPI. White arrows, fibroblast Smad3 activation; yellow arrows, cardiomyocyte Smad3 activation. (F) mRNA expression, normalized to Gapdh and then to sham data, assessed by real-time RT-PCR. n = 4 (sham); 10 (TAC plus C-Ab and TAC plus N-Ab). *P < 0.01 vs. sham; †P < 0.05 vs. TAC plus C-Ab.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts